Survival outcomes in EGFR-mutant versus wild-type locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy alone in the pre-PACIFIC/LAURA trial era: A systematic review and meta-analysis using reconstructed individual patient data.

Abstract excerpt

BACKGROUND AND AIMS: This study evaluated the prognostic impact of epidermal growth factor receptor (EGFR) mutations in locally advanced non-small cell lung cancer (NSCLC) treated with definitive chemoradiotherapy (CRT) alone in cohorts in which consolidation durvalumab or osimertinib was not administered as part of the initial post-CRT strategy. METHODS: We systematically reviewed studies comparing CRT outcomes...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Carcinoma, Non-Small-Cell Lung
• Share to Chemoradiotherapy